Financial Daily from THE HINDU group of publications
Tuesday, Aug 10, 2004
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Outlook


Divi's Labs sees Rs 400-cr turnover

Our Bureau

Hyderabad , Aug. 9

DIVI'S Laboratories, Hyderabad, has projected a turnover of Rs 400 crore for the financial year 2004-05. The company achieved a turnover of Rs 317 crore in the fiscal 2003-04, with a net profit of Rs 73 crore.

Giving the highlights of the company's performance at the 14th annual general body meeting on Monday, Mr Murali K. Divi, Chairman, said eight new products were developed, including levitiracetam, for which the company was the first to file the Drug Master File for the US market.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ocimum announces free bioinfo service

Arvind Mills gets shareholder nod to up FII limit to 49%
Natco Pharma launches drug for prostate cancer
Apollo Tyres opens outlet for farmers
ICAI calls for changes in ESOP norms
UB, Shaw Wallace bury the hatchet
More disclosure norms for foreign cos on cards?
CLB clears 248 cases
Service tax case: SC dismisses plea against tribunal order
Assocham against job quota in private sector
Laundry chain White Tiger plans Rs 70-cr expansion
Venkateswara group to set up bird breeding farm in West Bengal
Alps Industries to set up new plant
Universal Cables on diversification path
Rs 115-cr revival plan proposed for Hind Antibiotics
Hearing on SCM closure petition on August 23
Indian Hotels bullish on growth
Sona Koyo may source from Thailand post-FTA
Gujarat Ambuja to set up 1.2 mt facility at Dadri
Reliance Hirma unit to go commercial next year
Better earnings from oil firms seen this quarter
Divi's Labs sees Rs 400-cr turnover
What the CEOs took home

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line